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Abstract
Background: It has been well documented that phosphodiesterase-5 inhibitor, sildenafil (SIL) protects against myocardial
ischemia/reperfusion (I-R) injury. SIRT1 is part of the class III Sirtuin family of histone deacetylases that deacetylates proteins
involved in cellular stress response including those related to I-R injury.
Objective/Hypothesis: We tested the hypothesis that SIL-induced cardioprotection may be mediated through activation of
SIRT1.
Methods: Adult male ICR mice were treated with SIL (0.7 mg/kg, i.p.), Resveratrol (RSV, 5 mg/kg, a putative activator of
SIRT1 used as the positive control), or saline (0.2 mL). The hearts were harvested 24 hours later and homogenized for SIRT1
activity analysis.
Results: Both SIL- and RSV-treated mice had increased cardiac SIRT1 activity (P,0.001) as compared to the saline-treated
controls 24 hours after drug treatment. In isolated ventricular cardiomyocytes, pretreatment with SIL (1 mM) or RSV (1 mM)
for one hour in vitro also upregulated SIRT1 activity (P,0.05). We further examined the causative relationship between
SIRT1 activation and SIL-induced late cardioprotection. Pretreatment with SIL (or RSV) 24 hours prior to 30 min ischemia and
24 hours of reperfusion significantly reduced infarct size, which was associated with a significant increase in SIRT1 activity
(P,0.05). Moreover, sirtinol (a SIRT1 inhibitor, 5 mg/kg, i.p.) given 30 min before I-R blunted the infarct-limiting effect of SIL
and RSV (P,0.001).
Conclusion: Our study shows that activation of SIRT1 following SIL treatment plays an essential role in mediating the SIL-
induced cardioprotection against I-R injury. This newly identified SIRT1-activating property of SIL may have enormous
therapeutic implications.
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Introduction
Acute myocardial infarction (AMI) is a cardiovascular disease
that affects more than 1.5 million people in the United States
annually and is a major cause of mortality and morbidity
worldwide. In order to combat this serious health problem, there
have been extensive investigations during the past four decades in
searching for cardioprotective drugs that can be safely imple-
mented in the clinical settings against the devastating consequenc-
es of ischemic heart disease. Over the last 10 years, our laboratory
has demonstrated that phosphodiesterase-5 (PDE-5) inhibitors,
including sildenafil (ViagraH), vardenafil (LevitraH) and tadalafil
(CialisH), which are widely prescribed drugs to treat male erectile
dysfunction, can induce powerful cardioprotective effect against
ischemia-reperfusion (I-R) injury [1,2] and AMI-induced heart
failure [3] in rabbits and mice. We also identified a signaling
cascade that involves both endothelial and inducible nitric oxide
synthases (eNOS and iNOS) that promote generation of NO [2,4],
enhanced formation of cGMP and activation of protein kinase G
(PKG) [5] that result in cardioprotection.
Histone deacetylases (HDACs) have been shown to regulate
cardiac hypertrophy and other cardiac diseases [6]. Among three
recognized classes of HDACs, class I and class II are zinc-
dependent amidohydrolases, whereas class III is nicotinamide
adenine dinucleotide (NAD+)-dependent, which is termed as
sirtuins due to their homology with the yeast HDAC - Sir2.
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SIRT1 (sirtuin 1 - silent mating type information regulation 2
homolog 1) is part of the class III sirtuin family of HDACs and it
catalyzes a reaction in which nicotinamide is liberated from NAD+
and the acetyl group of the substrate is transferred to cleaved
NAD+, generating the novel metabolite O-acetyl-ADP ribose [7].
Since SIRT1 can deacetylate a variety of substrates, it is involved
in a broad range of physiological functions, including control of
gene expression, cell cycle regulation, apoptosis, DNA repair,
metabolism, oxidative stress response and aging [8]. Mice deficient
in Sir2 (the murine homolog of SIRT1) exhibited developmental
abnormality in the heart and rarely survive postnatally, suggesting
that SIRT1 has important function in the heart [9]. SIRT1
activity has also been correlated with metabolic state of cells and it
is believed to be nutrient regulated due in part to its dependency
on NAD [10,11]. SIRT1 is also an important regulator of cell
defenses and survival in response to stress [10,11]. For example,
SIRT1 provides protection against apoptosis and plays an essential
role in mediating the survival of cardiomyocytes under stress
in vitro [9]. Conversely, reduced SIRT1 activity in cardiomyocytes
contributes to myocyte cell death during heart failure [12]. More
recently, SIRT1 has been linked to the anti-ischemic cardiopro-
tection by 6-month caloric restriction [13], ischemic precondi-
tioning [14,15], or resveratrol (RSV) [16–18], the best known
small molecule activator of SIRT1, which allosterically binds to
SIRT1 and lowers the Michaelis constant of SIRT1 for both the
acetylated substrate and NAD+ [10,11].
The aim of this study was to determine if SIL induces protection
against I-R through activation of SIRT1. Based on the reported
NO-dependence of SIRT1 induction and cardioprotection by
caloric restriction [13,19], we hypothesized that SIRT1 activation
may be necessary for the cardioprotective effect of SIL, which is
also mediated by NO signaling [2,4]. We tested this hypothesis in
an in vivo murine model of regional myocardial I-R, and compared
with RSV, which served as a positive control for SIRT1 activation.
In addition, sirtinol, a putative inhibitor of SIRT1’s HDAC
activity [10,11] was used to determine the causative role of SIRT1
in SIL-induced late cardioprotection. Preliminary results of the
present study were presented at the 83rd Scientific Sessions of the
American Heart Association held at Chicago, U.S.A. in November
2010 [20].
Materials and Methods
Animals
Adult male ICR mice weighing 35.565 g were supplied by
Harlan Sprague Dawley Co. (Indianapolis, IN). All animal
experiments were conducted under the guidelines on humane
use and care of laboratory animals for biomedical research
published by the U.S. National Institutes of Health (NIH
Publication No. 85–23, revised 1996). All experimental prepara-
tions and protocols involving animals were reviewed and approved
by the Animal Care and Use Committee of Virginia Common-
wealth University.
Drugs and Preparation
Resveratrol powder was purchased from Sigma-Aldrich (St.
Louis, MO; item# R5010) and was dissolved in 15% dimethyl
sulfoxide (DMSO) and saline (0.9% NaCl containing 2.5 mM
CaCl2). Sildenafil citrate powder was kindly provided by Pfizer
and dissolved in saline. Sirtinol (Sigma-Aldrich; item# S7942) was
dissolved in 10% warm PBS and sonicated until homogenous.
Drug Treatment Regimen and in vivo Myocardial
Ischemia-reperfusion Protocol
As illustrated in Fig. 1, SIL (0.7 mg/kg), RSV (5 mg/kg), or
volume-matched saline (0.2 mL) was injected intraperitoneally
(i.p.) to the mice, 24 hours prior to I-R. In the SIRT1 inhibitor
studies, either sirtinol (5 mg/kg in 10% DMSO) or 10% DMSO
(0.2 ml) was given i.p. 30 min prior to I-R. The cardioprotective
dose of SIL was chosen based on our previous studies [1–3]. The
in vivo I-R surgery procedures were performed by a surgeon who
was blinded without knowing the type of drug administered to the
individual mice. The methodological details were identical to our
previous report [21]. The anesthetized (pentobarbital sodium,
70 mg/kg, i.p.), intubated, and mechanically ventilated mouse
underwent ligation of left anterior descending coronary artery for
30 min followed by 24 hours of reperfusion until myocardial
infarct size was determined.
Measurement of Infarct Size and Area at Risk
At the end of reperfusion, the mouse was re-anesthetized with
pentobarbital sodium and the heart was excised and mounted onto
a Langendorff apparatus for washing out blood with saline, and
then infused with 2 mL of 10% Evans blue dye and stored at
220uC. The frozen heart was cut into six to eight transverse slices,
which were stained with 10% triphenyl tetrazolium chloride
solution for 30 min at room temperature. The infarct area and
area at risk were measured using computer morphometry
(Bioquant 98) as described previously [21]. The risk area was
calculated as total ventricular area minus the area of cavities. The
infarct size was presented as percentage of the risk area.
Heart Tissue Sample Collection, Homogenization, Protein
Extraction and Purification for Measurement of SIRT1
Activity
Following the above-described treatments, the hearts were
harvested under pentobarbital anesthesia and stored at 280uC
until further use. A subgroup of SIL, RSV, or saline-treated mice
was subjected to I-R 24 hours after the drug treatment. The
SIRT1 inhibitor - sirtinol or DMSO was administered 30 min
prior to I-R. At the end of I-R protocol, the heart samples were
collected and stored as described above. The frozen hearts were
then ground with a mortar and pestle in liquid nitrogen. The
tissues were homogenized mechanically in a lysis buffer (without
protease inhibitors), containing 10 mM Tris-HCl (pH 7.4), NP-40
0.5%, 250 mM sucrose, 0.1 mM EGTA, 10 mM NaCl, 15 mM
MgCl2, 1 mM PMSF, 1 mM Na3VO4, and 1 mM NaF. The
tissue homogenates were spun through 4 mL of sucrose 30%,
10 mM Tris HCl (pH 7.5), 10 mM NaCl, and 3 mM MgCl2 at
1,3006g for 10 min at 4uC. The pellet was washed with cold
10 mM Tris-HCl (pH 7.5) and 10 mM NaCl. The nuclei were
suspended in 100 mL of extraction buffer containing 50 mM
HEPES KOH (pH 7.5), 420 mM NaCl, 0.5 mM EDTA Na2,
0.1 mM EGTA, and glycerol 10%, sonicated for 30 s, and stood
on ice for 30 min. After centrifugation at 13,000 rpm for 10 min,
an aliquot of the supernatant (crude extract nuclear) was used to
determine protein concentration using a Bio-Rad assay.
Subsequently, all of the protein samples extracted from the
heart tissues or isolated cardiomyocytes were immunoprecipitated
with SIRT1 antibody according to the manufacturers’ instruction.
In brief, 1 mg of SIRT1 primary antibody (Cyclex, Nagano, Japan)
was incubated with 250 mg of protein in extraction buffer
overnight at 4uC. Protein A agarose beads were then incubated
with the mixture overnight at 4uC. The mixture was then
centrifuged for 30 sec. The pellet was washed three times with
SIRT1 and Cardioprotection
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250 mL of 16 cell lysis buffer (Cyclex) and 250 mL of Sir2 assay
buffer (50 mM Tris-HCl, pH 8.8, 4 mM MgCl2, 0.5 mM DTT).
The pellet was then suspended in 100 mL of Sir2 assay buffer and
kept at 220uC until the measurement of SIRT1 activity.
Isolation of Ventricular Cardiomyocytes and Cell
Collection
The ventricular cardiomyocytes were isolated using an enzy-
matic technique identical to our previously reported method [4].
The freshly isolated cardiomyocytes were then suspended in
minimal essential medium (Sigma-Aldrich, item# M1018,
pH 7.35–7.45), containing 1.2 mM Ca2+, 12 mM NaHCO3,
2.5% fetal bovine serum, and 1% penicillin-streptomycin. The
cells were then plated onto 35-mm cell culture dishes that were
precoated with 20 mg/mL mouse laminin in phosphate-buffered
saline with 1% penicillin-streptomycin for 1 hour. After 1 hour of
plating, the cardiomyocytes were incubated with 1 mM SIL or
RSV, or without drug treatment (control). Following the
incubation, the cells were scraped from the plate and frozen at
280uC until further use for SIRT1 activity analysis.
SIRT1 Deacetylase Activity Assay
SIRT1 deacetylase activity was evaluated in the whole heart
lysate as well as cardiomyocyte lysate according to the previously
reported methods [22]. A deacetylase fluorometric assay kit (Sir2
Assay Kit, Cyclex) was used. The final reaction mixture (100 mL)
contained: 50 mM Tris-HCl (pH 8.8), 4 mM MgCl2, 0.5 mM
DTT, 0.25 mA/mL Lysyl endopeptidase, 1 mM trichostatin A,
Figure 1. Illustrated description of the experimental protocols using an in vivomodel of myocardial infarction induced by 30 min of
regional ischemia and 24 hours of reperfusion. Note that the drug pretreatments via i.p. injection were carried out 24 hours prior to the onset
of ischemia at the following dosage: Saline (0.2 ml, served as the Control group); RES (Resveratrol, 5 mg/kg); SIL (Sildenafil, 0.7 mg/kg).
doi:10.1371/journal.pone.0086977.g001
SIRT1 and Cardioprotection
PLOS ONE | www.plosone.org 3 January 2014 | Volume 9 | Issue 1 | e86977
200 mM NAD, and 10 mL of the crude extract nuclear sample.
The fluorescence intensity at 440 nm wavelength (exc. 340 nm)
was measured every 5 min for a total of 30 min immediately after
the addition of fluorosubstrate peptide, and then right after the
addition of stop solution. 60 mM of sirtinol - a SIRT1 inhibitor
and trichostatin A - an inhibitor of class I and II HDACs [9] were
also used. All measurements were performed in duplicate and the
results are reported as arbitrary units of relative fluorescence.
Western Blot Analysis for SIRT1 Expression
The murine hearts were homogenized and protein expression
was analyzed using techniques we previously reported [5]. In brief,
the heart tissues were ground with a mortar and pestle under
liquid nitrogen into fine powder. Total soluble protein was
extracted from the heart lysates with RIPA buffer plus PMSF,
protease inhibitors, Na3VO4, and b-mercaptoethanol. A mechan-
ical homogenizer was used to homogenize the samples, which
were subsequently sonicated. The homogenate was then centri-
fuged at 14,0006g for 15 min at 4uC and the supernatant was
recovered and stored at 280oC until used. Following quantifica-
tion of the sample protein concentration using a Bio-Rad assay,
100 mg of protein from each sample was separated by SDS-PAGE
on a 7.5% polyacrylamide gel, transferred onto nitrocellulose
membrane and then blocked with 5% nonfat dry milk in TBST
(10 mM Tris-HCl, pH 7.4, 100 mM NaCl, and 0.1% Tween 20)
for 1 h. The membrane was incubated with a primary antibody (at
1:1000 dilution) for SIRT1 (Sigma-Aldrich) or b-actin (Santa Cruz
Biotechnology) overnight at 4uC. The membrane was then washed
with TBST and incubated with secondary antibody (1:2000
dilution, 1 h at room temperature). The blots were developed
using a chemiluminescent system (ECL Plus; Amersham Biosci-
ences). Densitometry was used to quantify the optical density of
SIRT1 for each band and normalized with the intensity of b-actin,
presented as ratio of SIRT1/b-actin [4].
Data Analysis and Statistics
Data are presented as mean 6 S.E. The differences between
groups were analyzed with one-way analysis of variance followed
by Student-Newman-Keuls post hoc test for pair-wise comparison.
P,0.05 was considered to be statistically significant.
Results
Effect of SIRT1 Inhibitor on SIL-induced Infarct-limiting
Cardioprotection
As shown in Fig. 2A (Mean 6 SE, n= 6/group), the saline-
treated control mice had large infarct size (48.365.9% of the risk
area) following 30 min of ischemia and 24 hours of reperfusion.
SIL significantly reduced myocardial infarct size to 22.367.6%
(P,0.001) as compared to the saline group. RSV, a putative
activator of SIRT1, also significantly reduced infarct size to
17.463.7% (P,0.001). The infarct-limiting cardioprotection by
SIL or RSV was abrogated by sirtinol – a SIRT1 inhibitor
administered i.p. 30 min prior to ischemia (Fig. 1A), indicated by
the large infarct size in SIL+Sirtinol group (38.962.5%) and
RSV+Sirtinol group (37.161.8%), which were not significantly
different from the Saline (48.365.9%) or Saline+Sirtinol
(52.561.2%) groups (P.0.05). 10% DMSO (the solvent of
sirtinol) alone had no significant effect on infarct size and it also
did not block the protective effects of SIL and RSV, as indicated
by the significantly smaller infarct size in the SIL+DMSO and
RSV+DMSO groups as compared with Saline+DMSO group
(Fig. 2A). All of the drug treatments did not affect the amount of
area at risk, as indicated in Fig. 2B.
Effect of SIL on SIRT1 Deacetylase Activity in Intact Heart
and Isolated Cardiomyocytes
We measured the relative fluorescence of deacetylated SIRT1
substrate in the homogenized heart samples following various drug
treatment regimens. As shown in Fig. 3A, SIL (0.7 mg/kg, i.p.) or
RSV (5 mg/kg, i.p.) resulted in a significant increase in cardiac
SIRT1 activity 24 hours after the drug pre-treatment, as
compared with the Saline controls (P,0.001). The levels of
SIRT1 activation by SIL and RSV were largely comparable (i.e.
P.0.05 SIL versus RSV). Furthermore, we investigated the direct
effect of SIL or RSV on SIRT1 activity in ventricular myocytes in
an in vitro cultured cell model. We observed that 1 hour incubation
with 1 mM SIL or RSV led to a significant increase in SIRT1
activity in the isolated cardiomyocytes (P,0.05; Fig. 3B).
As shown in Fig. 4, SIL or RSV pre-treatment (24 hours prior to
I-R) significantly enhanced SIRT1 activity in the post-I-R heart as
compared with the Saline-treated controls (P,0.0001). The
Figure 2. Infarct size was significantly
(P,0.001 vs. saline controls) reduced in the Sildenafil-treated, Resver-
atrol-treated, Sildenafil+DMSO-treated, and Resveratrol+DMSO-treated
groups. Sirtinol abolished the cardioprotective effects of both Sildenafil
and Resveratrol. n = 6/Group, * = P,0.001 vs. Saline Controls,
#=P,0.05 vs. other groups. B. Area at Risk. The area at risk was
presented as percentage of the total left ventricular area that
underwent ischemia. n = 6/group, no significant difference was found
among all groups.
doi:10.1371/journal.pone.0086977.g002
SIRT1 and Cardioprotection
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inhibitory effect of sirtinol on cardiac SIRT1 activities in SIL or
RSV-treated mice was also apparent (P,0.05; Fig. 4). I-R alone
did not alter cardiac SIRT1 activity.
Effect of SIL on Cardiac SIRT1 Protein Expression
Western blot analysis shows increase in cardiac SIRT1 protein
expression 24 hours following the SIL treatment (Figure 5), which
was confirmed by the densitometric results expressed as SIRT1/b-
actin ratio (P,0.05, SIL group versus Saline group, Figure 5 lower
panel).
Discussion
The class III HDAC family member SIRT1 has been shown to
protect against cardiovascular diseases, cancer, and neurodysfunc-
tion [10]. Considering its functional importance in the control of
gene expression, cell cycle regulation, apoptosis, DNA repair,
metabolism, oxidative stress response and aging [8], identification
of new pharmacological interventions to regulate SIRT1 activity
for therapeutic interventions in human disorders has been a focal
point of intensive research. Our results provide the first evidence
which shows that cardioprotective dose of SIL - a selective PDE-5
inhibitor enhances SIRT1 activity in the heart (Fig. 3). Further-
more, our data shows that SIRT1 activation plays a causative role
in SIL-induced late cardioprotection, because SIRT1 inhibitor –
sirtinol completely blocked the infarct-limiting effect of SIL
(Fig. 2A). It is notable that the SIRT1 activation or upregulation
by SIL pretreatment was observed in unstressed (i.e., non-ischemic)
(Fig. 3A, Fig. 5) as well as in hearts following I-R injury (Fig. 4).
We further investigated if SIL could directly augment SIRT1
activity in the isolated mouse cardiomyocytes in vitro. Our results
show that incubation with 1 mM SIL (an established cytoprotective
dose in our previous publications [4,5] in the culture medium
(37uC, 5% CO2) for 1 hour significantly activated SIRT1 in the
isolated cardiomyocytes (Fig. 3B). These results suggest that SIL
rapidly activates SIRT1 in cardiomyocytes and mediates protec-
tion during a wide range of time window, i.e. 24 hours. An
interesting observation in the present study is that the cardiopro-
tective dose of SIL activated SIRT1 similar to RSV, a putative
activator of SIRT1 [16–18]. The magnitude of increase in cardiac
SIRT1 activity following treatment with low dose SIL (0.7 mg/kg)
was similar to the one induced by 5 mg/kg RSV (Fig. 3A and
Fig. 4).
There could be other advantages for SIL considering its well
proven safety profiles as a FDA-approved and widely prescribed
drug for managing patients with male erectile dysfunction and
pulmonary hypertension. Interestingly, the oral administration of
RSV attenuated established monocrotaline-induced pulmonary
hypertension indices, including right ventricular systolic pressure,
right ventricular hypertrophy, and medial thickening of intrapul-
Figure 3. Enhanced SIRT1 deacetylase activity in heart tissues
from the mice treated i.p. with single dose of resveratrol (RSV,
5 mg/kg) or sildenafil (SIL, 0.7 mg/kg) for 24 hours (Graph A);
*P,0.001 vs. Saline (n=3/group). Graph B shows SIRT1 deacetylase
activity in isolated cardiomyocytes following 1 hour incubation with
RSV or SIL (1 mM, n= 3/group) in vitro. *P,0.05 vs. the untreated
control group.
doi:10.1371/journal.pone.0086977.g003
Figure 4. SIRT1 deacetylase activity in the heart tissues from
the mice pretreated (i.p.) with saline (0.2 mL), RSV (5 mg/kg),
and SIL (0.7 mg/kg) 24 hours prior to 30 min of regional
ischemia and 24 hours of reperfusion. The SIRT1 inhibitor - sirtinol
(5 mg/kg) was administered (i.p.) 30 min prior to the onset of ischemia.
The Sham group serves as surgical controls, whereas Saline and DMSO
groups serve as the drug solvent/vehicle controls. Data are Mean 6 SE
(n = 3/group). *P,0.0001 vs. Control group. #P,0.05 vs. all other
groups.
doi:10.1371/journal.pone.0086977.g004
SIRT1 and Cardioprotection
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monary arteries [23]. Moreover, SIRT1 inhibition augmented
proliferation of pulmonary artery smooth muscle cells, as assessed
by DNA mass and suppressed atrogin mRNA expression. Thus the
SIRT1-activating effects of SIL reported in the present study
provides a new and exciting mechanistic explanation to utilize this
drug and potentially other PDE-5 inhibitors in reducing ischemic
heart tissue damages as well as pulmonary hypertension,
considering the essential role played by SIRT1 in regulating cell
defenses and survival in response to stress [10,11]. Nevertheless,
further investigations should be conducted to elucidate the
signaling network linking PDE-5 inhibition with SIL and SIRT1
activation in the heart, which leads to cardioprotection against I-R
injury. In light of our previous studies [2,4] showing SIL
significantly enhances levels of mRNA and/or protein expression
of eNOS and iNOS in intact heart and isolated cardiomyocytes,
we postulate that this NO signaling may have a significant role in
the activation of SIRT1 as previously shown in the calorie
restriction models [13,19]. Moreover, it has been shown that
chronic inhibition of NOS blocked the calorie restriction-induced
increase in nuclear SIRT1 content as well as ischemic tolerance in
the heart [13,19]. However, the exact signal transduction cascade
and the role of protein kinases such as PKG in activating SIRT1
remain to be investigated. It is notable that the effects of SIL on
other members of Sir2 family such as SIRT3– a cardiac abundant
isoform have not yet been investigated and may represent an
additional important target of PDE-5 inhibitors.
Conclusion
We have demonstrated that SIL-induced late cardioprotection
is mediated by SIRT1 activation. This newly identified SIRT1-
activating property of SIL may have enormous therapeutic
implications and benefits in reducing not only the myocardial I-
R injury, but also other types of cardiovascular disorders related to
aging and metabolic dysregulation such as Type 2 diabetes.
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